Rising Cancer Diagnoses in Young Adults: Lifestyle Changes and Early Screenings can Lower Risks

 

In recent years, a troubling trend has emerged: a noticeable rise in cancer diagnoses among young adults. This discussion is particularly timely following the news of Princess Kate Middleton’s cancer diagnosis and the growing recognition that cancer is no longer a disease confined to older populations. Research indicates that environmental and behavioral factors, alongside genetics, may be contributing to this increase.

Why is there an increase in cancer diagnoses among younger populations, and what screenings should be prioritized to detect it early?

In this episode of “I Don’t Care,” host Dr. Kevin Stevenson talks with Dr. Najeeb Al Hallak, the medical oncologist and co-leader of the gastrointestinal and neuroendocrine oncology multidisciplinary team at the Barbara Ann Karmanos Cancer Institute. They delve into the importance of early cancer screenings and how primary care physicians can play a pivotal role in early detection and prevention.

Main Points of Conversation:

  • The importance of early cancer screenings for young adults, especially for those with familial or genetic predispositions.
  • The impact of environmental and behavioral factors on cancer risk in younger populations.
  • Specific cancer screening recommendations for young adults, including colonoscopies, mammograms, and genetic testing.

Dr. Najeeb Al Hallak is a distinguished medical oncologist specializing in gastrointestinal cancers. He serves as an associate professor in oncology at Wayne State University and co-leads the gastrointestinal and neuroendocrine oncology multidisciplinary team at the Barbara Ann Karmanos Cancer Institute. His research focuses on gastrointestinal malignancies, clinical trials, and the development of new cancer treatments.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…